MRK Stock Recent News

MRK LATEST HEADLINES

MRK Stock News Image - Zacks Investment Research

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports first-quarter 2024 earnings.

Zacks Investment Research 2024 Apr 22
MRK Stock News Image - Zacks Investment Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.

Zacks Investment Research 2024 Apr 22
MRK Stock News Image - CNBC

CNBC's Jim Cramer said next week's PCE index report will be the real gauge of inflation.

CNBC 2024 Apr 19
MRK Stock News Image - Zacks Investment Research

In the most recent trading session, Merck (MRK) closed at $125.37, indicating a +0.25% shift from the previous trading day.

Zacks Investment Research 2024 Apr 17
MRK Stock News Image - The Motley Fool

Big pharma stocks, on balance, have been trading at a discount relative to the broader market for decades. Merck, a tier 1 U.S. pharmaceutical company, has been breaking out of this trend in 2024.

The Motley Fool 2024 Apr 15
MRK Stock News Image - The Motley Fool

Moderna and Merck are collaborating on a personalized cancer vaccine. That vaccine program just disclosed some new data from the clinic.

The Motley Fool 2024 Apr 12
MRK Stock News Image - Zacks Investment Research

In the closing of the recent trading day, Merck (MRK) stood at $126.15, denoting a -0.47% change from the preceding trading day.

Zacks Investment Research 2024 Apr 11
MRK Stock News Image - Zacks Investment Research

Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.

Zacks Investment Research 2024 Apr 09
MRK Stock News Image - Zacks Investment Research

Merck (MRK) concluded the recent trading session at $127.99, signifying a +0.26% move from its prior day's close.

Zacks Investment Research 2024 Apr 05
MRK Stock News Image - Zacks Investment Research

Merck's (MRK) phase III study will evaluate KRAS G12C inhibitor candidate MK-1084 for first-line treatment of certain patients with metastatic NSCLC.

Zacks Investment Research 2024 Apr 05
10 of 50